Skip to content
BiologicalX

Dosage guide

Melatonin dosage

Melatonin dosing: typical range, frequency, half-life, onset, routes. Evidence-tiered.

At a glance

Typical dose
0.5mg
Half-life
0.75hr
Frequency
daily, 30 to 60 minutes before target sleep time
Routes
oral, sublingual

Protocol

  1. 1

    Measure the dose

    Typical Melatonin dose is 0.5 mg. Use a weight-based calculator for individual adjustments.

    Open tool →
  2. 2

    Set the frequency

    Administer daily, 30 to 60 minutes before target sleep time. Half-life of 0.75 hours anchors the dosing interval.

    Open tool →
  3. 3

    Cycle if needed

    No formal cycling required; many users take only as needed for jet lag or shift work

    Open tool →
  4. 4

    Monitor for side effects

    Watch for: vivid dreams; morning grogginess (higher doses); headache; dizziness. Stop or reduce dose if tolerability breaks down.

Why this dose

Agonist at MT1 and MT2 receptors in the suprachiasmatic nucleus, signaling biological night and promoting sleep-onset gating plus circadian phase shifts.

The typical 0.5 mg dose is the figure most commonly used in published protocols for Melatonin. Treat the label as a starting point: body weight, training status, sleep, diet, and concurrent medications all shift the effective dose-response curve in real users.

How to administer

Melatonin is administered via the oral or sublingual routes. Oral dosing is straightforward: take with water, with or without food unless specifically noted. Sublingual dosing requires holding the dose under the tongue for 60 to 90 seconds before swallowing to maximize mucosal absorption.

Onset of action runs around 30 minutes after administration. Peak effect lands near 1 hour post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: Immediate-release ~30 to 50 minutes; extended-release formulations ~3.5 to 4 hours

Cycling and tolerance

No formal cycling required; many users take only as needed for jet lag or shift work

Effects to expect at typical dose

  • Shortens sleep onset latency by ~7 to 12 minutes at physiological 0.3 to 1 mg doses
  • Advances circadian phase when taken 30 to 60 minutes before target bedtime, useful for jet lag and shift work
  • Does not meaningfully increase total sleep time in healthy adults without circadian misalignment
  • Endogenous nighttime production is not suppressed by short-term exogenous supplementation
  • Higher doses (3 to 10 mg) raise plasma levels above physiological range and often increase morning grogginess
  • Effective for delayed sleep-wake phase disorder and reducing jet-lag severity in eastward travel

Best-graded outcomes

  • A Sleep onset latency : 7 to 12 minute reduction at low doses (Adults at 0.3 to 1 mg).
  • A Circadian phase advance (jet lag) : Robust reductions in jet-lag severity (Eastward travel, shift work).
  • A Sleep onset in pediatric ASD : Robust onset latency reductions; Cochrane support (Children with autism spectrum disorder).

Side effects and interactions

Common side effects

  • vivid dreams
  • morning grogginess (higher doses)
  • headache
  • dizziness

Notable interactions

  • fluvoxamine (major): CYP1A2 inhibition raises melatonin levels substantially
  • warfarin (moderate): possible increased bleeding risk
  • benzodiazepines and alcohol (moderate): additive sedation
  • antihypertensives (minor): may alter blood pressure response

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full Melatonin profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status
allowed
DEA / Rx
OTC supplement in US; Rx in UK, EU, Japan, Australia
Pregnancy
Insufficient data; not routinely recommended
Legal status
OTC in US; prescription in UK, EU, Japan

Do not use if

  • autoimmune disease (theoretical)
  • concurrent anticoagulant therapy without monitoring

Related calculators

Related research